Wipro helped a top pharma company develop a non-invasive solution to ensure best health outcome for renal transplant patients
Client Background
The client is a Big Pharma headquartered in New York City. It manufactures prescription drugs in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
Industry Landscape
Amid the revenue pressures triggered by patent cliff and the imperatives of outcome-based healthcare, Life Sciences organizations are recognizing the increased role of patients in disease management. Thus, they need innovative models to engage their target actors - Patients and Physicians.
Opportunity
Our client launched a speciality nephrology drug used as immunosuppressant post renal transplants, the first such drug to be approved in more than a decade. Despite a limited market, the drug was expected to be highly profitable and increase our client’s market share significantly. The client wanted to ensure that the drug delivers the expected health outcome and repeat Rx (prescription) and patient satisfaction.
Solution
Wipro was tasked with creating a solution to ensure expected health outcome of the nephrology drug while helping with repeat Rx and patient satisfaction.
We conducted requirement gathering sessions with:
We conducted requirement gathering sessions with:
We developed a platform-independent mobile app, which, according to the Medical Devices Directive, in its own right qualifies as a Class I medical device owing to its use and for its safety and efficacy.
The app facilitates physicians with:
Wipro created a security feature so that only registered physicians could use the app. A process was designed to validate credentials with the master ANA DB server. We also created web services so that the app could connect to the server through cloud.
The integration was unique with the mobile app on cloud and in-house server behind the firewall.
Our in-house regulatory consultant ensured the app had robust human error correction mechanism through in-person sessions with the User Acceptance Testing (UAT) HCP group.
Business Impact
Improved drug adherence